-
EP3287447
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3287447
| EP3287447 - SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 12.02.2019 Database last updated on 20.05.2024 | |
| Former | Request for examination was made Status updated on 31.08.2018 | ||
| Former | The application has been published Status updated on 26.01.2018 | Most recent event Tooltip | 14.05.2024 | New entry: Reply to examination report | Applicant(s) | For all designated states Grünenthal GmbH Zieglerstrasse 6 52078 Aachen / DE | [2018/09] | Inventor(s) | 01 /
GRUSS, Michael Hermannstrasse 8 52062 Aachen / DE | 02 /
KRASZEWSKI, Magda Alfonsstrasse 38 52070 Aachen / DE | [2018/09] | Representative(s) | Kutzenberger Wolff & Partner Waidmarkt 11 50676 Köln / DE | [N/P] |
| Former [2018/09] | Kutzenberger Wolff & Partner Theodor-Heuss-Ring 23 50668 Köln / DE | Application number, filing date | 17191453.4 | 22.07.2011 | [2018/09] | Priority number, date | EP20100007672 | 23.07.2010 Original published format: EP 10007672 | [2018/09] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3287447 | Date: | 28.02.2018 | Language: | EN | [2018/09] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 04.01.2018 | Classification | IPC: | C07D275/06, C07D291/06, C07C215/54, A61K31/137, C07D239/545, C07C59/255 | [2018/09] | CPC: |
C07D275/06 (EP,US);
C07C215/54 (EP,CN,KR,US);
A61K31/137 (EP,KR,US);
A61P25/04 (EP);
C07C53/08 (EP);
C07C53/126 (EP);
C07C55/02 (EP,US);
C07C55/06 (EP);
C07C55/08 (EP,CN,US);
C07C55/10 (EP);
C07C55/20 (EP,CN,US);
C07C57/12 (EP);
C07C57/145 (EP);
C07C57/15 (EP,CN,US);
C07C57/44 (EP);
C07C59/08 (EP);
C07C59/105 (EP);
C07C59/11 (EP);
C07C59/245 (EP);
C07C59/255 (EP,KR);
C07C59/265 (EP);
C07C59/285 (EP);
C07C63/06 (EP);
C07C63/08 (EP,US);
C07C63/36 (EP,US);
C07C65/03 (EP);
C07C65/11 (EP,CN,US);
C07C69/78 (EP,CN);
C07D213/80 (EP,CN,US);
C07D239/545 (EP,US);
C07D291/06 (EP,US);
A61K31/455 (EP,US);
C07B2200/07 (EP,US);
C07B2200/13 (CN)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/40] |
| Former [2018/09] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | SALZE ODER KOKRISTALLE AUS 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYLPROPYL)PHENOL | [2018/09] | English: | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | [2018/09] | French: | SELS OU CO-CRISTAUX DE 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)- PHÉNOL | [2018/09] | Examination procedure | 15.09.2017 | Date on which the examining division has become responsible | 27.08.2018 | Amendment by applicant (claims and/or description) | 28.08.2018 | Examination requested [2018/40] | 15.02.2019 | Despatch of a communication from the examining division (Time limit: M06) | 26.04.2019 | Observations by third parties | 08.08.2019 | Reply to a communication from the examining division | 20.11.2019 | Despatch of a communication from the examining division (Time limit: M11) | 11.08.2020 | Observations by third parties | 26.10.2020 | Reply to a communication from the examining division | 20.11.2020 | Observations by third parties | 18.12.2020 | Observations by third parties | 21.01.2021 | Despatch of a communication from the examining division (Time limit: M04) | 19.05.2021 | Observations by third parties | 31.05.2021 | Reply to a communication from the examining division | 10.11.2021 | Observations by third parties | 12.07.2022 | Despatch of a communication from the examining division (Time limit: M08) | 20.03.2023 | Observations by third parties | 14.04.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 23.06.2023 | Reply to a communication from the examining division | 16.11.2023 | Despatch of a communication from the examining division (Time limit: M06) | 13.05.2024 | Reply to a communication from the examining division | Parent application(s) Tooltip | EP11743775.6 / EP2595971 | Divisional application(s) | EP19191640.2 / EP3597628 | EP19206638.9 / EP3636629 | EP19214270.1 / EP3650439 | EP19214275.0 / EP3656765 | EP19215642.0 / EP3653600 | EP20204993.8 / EP3800179 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 23.06.2023 | Request for further processing filed | 23.06.2023 | Full payment received (date of receipt of payment) Request granted | 30.06.2023 | Decision despatched | Fees paid | Renewal fee | 15.01.2018 | Renewal fee patent year 03 | 15.01.2018 | Renewal fee patent year 04 | 15.01.2018 | Renewal fee patent year 05 | 15.01.2018 | Renewal fee patent year 06 | 15.01.2018 | Renewal fee patent year 07 | 11.07.2018 | Renewal fee patent year 08 | 15.07.2019 | Renewal fee patent year 09 | 14.07.2020 | Renewal fee patent year 10 | 15.07.2021 | Renewal fee patent year 11 | 15.06.2022 | Renewal fee patent year 12 | 14.06.2023 | Renewal fee patent year 13 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]EP0693475 (GRUENENTHAL GMBH [DE]) [I] 1-16 * examples 24,25; claims 1-10 *; | [X]WO02067651 (GRUENENTHAL GMBH [DE], et al) [X] 1,6-16 * example 1; claims 1,12,22-39 *; | [A]WO2008110323 (GRUENENTHAL GMBH [DE], et al) [A] 1-16 * page 28; claims 1-8 *; | [A]WO2009067703 (NECTID INC [US], et al) [A] 1-16* claims 1,2,18-25 * | by applicant | EP0693475 | EP1439829 | - CHEMICAL ABSTRACTS, Database accession no. 175591-23-8 | other | US6248737 | US6696496 | US2005176790 | USRE39593E | US7569610 | EP0693475 | EP0693475 | US6344558 | US2005058706 | WO2006034451 | WO2007067727 | EP1612203 | WO2007144005 | WO2008021559 | US2008269326 | WO2009007853 | WO2012010316 | EP2595971 | - PHILIP L. GOULD, "Salt selection for basic drugs", International Journal of Pharmaceutics, (19860000), vol. 33, pages 201 - 217, XP002074725 DOI: http://dx.doi.org/10.1016/0378-5173(86)90055-4 | - Anonymous, "Highlights of Prescribing Information on Tradename™ (tapentadol)", Ortho-McNeil-Janssen Pharmaceuticals, Inc., (200811), pages 1 - 27, XP055764961 | - David Lee, Suresh Doddapaneni, "APPLICATION NUMBER: 22-304 Clinical Pharmacology and Biopharmaceutics Review(s)", Centre for Drug Evaluation and Research, (20080930), pages 1 - 147, XP055764971 | - ABU T.M. SERAJUDDIN, "Salt formation to improve drug solubility", Advanced Drug Delivery Reviews, (20070000), vol. 59, doi:10.1016/j.addr.2007.05.010, pages 603 - 616, XP022211982 DOI: http://dx.doi.org/10.1016/j.addr.2007.05.010 | - Steffen Paulekuhn G; Jennifer B Dressman; Christoph Saal, "Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database", J. Med. Chem., (20070000), vol. 50, doi:10.1021/jm701032y, pages 6665 - 6672, XP055536811 DOI: http://dx.doi.org/10.1021/jm701032y | - JIE LU, Sohrab Rohani, "Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs)", Current Medicinal Chemistry, (20090000), vol. 16, no. 7, pages 884 - 905, XP055764976 | - EXHIBIT-E1 Evidence Affidavit with Experimental Data for Repition of Prior Art process.pdf | - David Lee, Suresh Doddapaneni, "APPLICATION NUMBER: 22-304 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S)", CENTER FOR DRUG EVALUATION AND RESEARCH, (20080930), pages 1 - 147, XP055764971 | - G Steffen Paulekuhn et al, "Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database", Journal of Medicinal Chemistry, American Chemical Society, US, US , (20071227), vol. 50, no. 26, doi:10.1021/jm701032y, ISSN 0022-2623, pages 6665 - 6672, XP002651069 DOI: http://dx.doi.org/10.1021/jm701032y | - JIE LUSOHRAB ROHANI, "Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs", Current Medicinal Chemistry, (20090000), vol. 16, pages 884 - 905, XP055764976 | - Anonymous, "Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry", U.S. Department of Health and Human Services Food and Drug Administration, (20180201), pages 1 - 4, XP055814449 | - Anonymous, "Nucynta®ER Highlights of Prescribing Information", U.S. food and Dug Administration, (2008), page 34pp | - David Lee; Suresh Doddapaneni, "APPLICATION NUMBER: 22-304 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S)", CENTER FOR DRUG EVALUATION AND RESEARCH, (20080930), pages 1-3, 10 - 11, XP055764971 | - G. STEFFEN PAULEKUHN et al., "Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database", J. Med. Chem., (20070000), vol. 50, doi:10.1021/jm701032y, pages 6665 - 6672, XP055536811 DOI: http://dx.doi.org/10.1021/jm701032y | - JIE LUSOHRAB ROHANI, "Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs)", Current Medicinal Chemistry, (20090000), vol. 16, pages 884 - 905, XP055764976 | - Anonymous, "Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry", U.S. Department of Health and Human Services Food and Drug Administration, (20180200), pages 1 - 4, XP055814449 |